Aridis Pharmaceuticals, Inc. (ARDS)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Breakdown | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -29.12 Million | -22.93 Million | -20.47 Million | -8.15 Million | -24.27 Million | -17.55 Million |
| Net Income | -30.37 Million | -42.19 Million | -22.33 Million | -29.68 Million | -22.1 Million | -24.65 Million |
| Depreciation & Amortization | 487 Thousand | 435 Thousand | 337 Thousand | 338 Thousand | 283 Thousand | 62 Thousand |
| Deferred income taxes | - | -722 Thousand | - | - | - | - |
| Stock-based compensation | 1.47 Million | 2.25 Million | 2.12 Million | 2.01 Million | 1.65 Million | 1.6 Million |
| Change in working capital | -1.29 Million | 10.51 Million | -617 Thousand | 18.22 Million | -2.51 Million | 277 Thousand |
| Other non-cash items | 577 Thousand | 6.77 Million | 9000.00 | 951 Thousand | -1.59 Million | 5.15 Million |
| Investing Cash Flow | -82 Thousand | -530 Thousand | -367 Thousand | -174 Thousand | -1.67 Million | -698 Thousand |
| Investments in PPE | -82 Thousand | -530 Thousand | -367 Thousand | -174 Thousand | -677 Thousand | -698 Thousand |
| Acquisitions | - | - | - | - | -1 Million | - |
| Investment purchases | - | - | - | - | -1 Million | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | 1 Million | - |
| Financing Cash Flow | 14.78 Million | 34.72 Million | 8.67 Million | 4.99 Million | 25.08 Million | 21.06 Million |
| Debt repayment | -1.8 Million | -5 Million | -715 Thousand | - | - | - |
| Dividends payments | - | -4.12 Million | - | - | -1.35 Million | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 12.6 Million | 29.71 Million | 7.94 Million | 4.95 Million | 25.07 Million | - |
| Other Financing Activities | 3.97 Million | 9.13 Million | 729 Thousand | 35 Thousand | 1.36 Million | 21.06 Million |
| Accounts receivables | -1 Million | - | - | 1.66 Million | -1.66 Million | 67 Thousand |
| Accounts payables | -2.93 Million | 2.65 Million | -83 Thousand | -469 Thousand | 2.09 Million | 431 Thousand |
| Inventory | - | - | - | -2.54 Million | -2.85 Million | -341 Thousand |
| Other working capital | 2.63 Million | 7.86 Million | -534 Thousand | 19.58 Million | -97 Thousand | 120 Thousand |
| Cash at beginning of period | 19.98 Million | 8.73 Million | 20.89 Million | 24.23 Million | 25.09 Million | 22.29 Million |
| Cash at end of period | 5.55 Million | 19.98 Million | 8.73 Million | 20.89 Million | 24.23 Million | 25.09 Million |
| Capital Expenditure | -82 Thousand | -530 Thousand | -367 Thousand | -174 Thousand | -677 Thousand | -698 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -14.42 Million | 11.25 Million | -12.16 Million | -3.34 Million | -859 Thousand | 2.8 Million |
| Free Cash Flow | -29.2 Million | -23.46 Million | -20.84 Million | -8.33 Million | -24.94 Million | -18.25 Million |
| Breakdown | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 FY | 2022 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -83 Thousand | 12.14 Million | -6.81 Million | -6.38 Million | -30.37 Million | -8.23 Million |
| Depreciation & Amortization | 59 Thousand | 63 Thousand | 87 Thousand | 100 Thousand | 487 Thousand | 125 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 200 Thousand | 210 Thousand | 245 Thousand | 318 Thousand | 1.47 Million | 349 Thousand |
| Change in working capital | -1.83 Million | -16.82 Million | 1.87 Million | -1.66 Million | -1.29 Million | 2.67 Million |
| Other non-cash items | 676 Thousand | 69 Thousand | 605 Thousand | -921 Thousand | 577 Thousand | 823 Thousand |
| Investing Cash Flow | - | 14 Thousand | - | -49 Thousand | -82 Thousand | - |
| Investments in PPE | - | - | - | -49 Thousand | -82 Thousand | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 999 Thousand | 3.02 Million | 263 Thousand | 11.03 Million | 14.78 Million | -554 Thousand |
| Debt repayment | -735 Thousand | -3.23 Million | -1.48 Million | -1.35 Million | -1.8 Million | -450 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 1.73 Million | 1000.00 | 2.05 Million | 12.6 Million | 12.6 Million | - |
| Other Financing Activities | -738 Thousand | 3.02 Million | -308 Thousand | -227 Thousand | 3.97 Million | -554 Thousand |
| Accounts receivables | -217 Thousand | -200 Thousand | 1 Million | -1 Million | -1 Million | 1 Million |
| Accounts payables | -827 Thousand | 2.11 Million | 1.81 Million | -1.92 Million | -2.93 Million | 1.67 Million |
| Inventory | - | 701 Thousand | - | - | - | - |
| Other working capital | -791 Thousand | -19.44 Million | -934 Thousand | 1.25 Million | 2.63 Million | 3000.00 |
| Cash at beginning of period | 519 Thousand | 1.82 Million | 5.55 Million | 3.13 Million | 19.98 Million | 7.95 Million |
| Cash at end of period | 535 Thousand | 519 Thousand | 1.82 Million | 5.55 Million | 5.55 Million | 3.13 Million |
| Capital Expenditure | - | - | - | -49 Thousand | -82 Thousand | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 16 Thousand | -1.3 Million | -3.73 Million | 2.42 Million | -14.42 Million | -4.81 Million |
| Free Cash Flow | -983 Thousand | -4.34 Million | -4 Million | -8.6 Million | -29.2 Million | -4.26 Million |
SCHW-PJ
CRES
XYL
SEER
RAPP
TAR